Eli Lilly’s Weight-Loss Drug, Mounjaro, Sparks an Epic Run in Pharma Shares

Introduction Over years, Eli Lilly has undergone a significant transformation, positioning itself as the world’s most valuable drugmaker. Renowned for psychiatric drugs such as Prozac, the company faced several challenges in revenue generation during the 2010s due to patent expiration of its innovative drugs. However, a strategic shift and a focus on innovative treatments have

Novartis Steps Back from Cytokinetics Acquisition Amid Stock Plunge

Introduction In a surprising turn of events, Swiss pharmaceutical giant Novartis has decided to step back from the pursuit of much-anticipated acquisition of Cytokinetics, a US based cardiovascular drug developer. This sudden decision has sent ripples through the market, prompting a significant drop in Cytokinetics’ stock value and leaving investors and industry analysts questioning the